Neurocrine Biosciences, Inc.’s recently made public that its Director RASTETTER WILLIAM H unloaded Company’s shares for reported $2.09 million on Aug 15 ’24. In the deal valued at $146.69 per share,14,250 shares were sold. As a result of this transaction, RASTETTER WILLIAM H now holds 37,491 shares worth roughly $5.44 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, LYONS GARY A sold 11,570 shares, generating $1,740,450 in total proceeds. Upon selling the shares at $150.43, the Director now owns 119,047 shares.
Before that, ABERNETHY MATT sold 14,100 shares. Neurocrine Biosciences, Inc. shares valued at $2,120,347 were divested by the Chief Financial Officer at a price of $150.38 per share. As a result of the transaction, ABERNETHY MATT now holds 31,528 shares, worth roughly $4.57 million.
Wells Fargo upgraded its Neurocrine Biosciences, Inc. [NBIX] rating to an Overweight from a an Equal weight in a research note published on April 24, 2024; the price target was increased to $170 from $140. Deutsche Bank began covering NBIX with “Buy” recommendation on December 12, 2023.
Price Performance Review of NBIX
On Friday, Neurocrine Biosciences, Inc. [NASDAQ:NBIX] saw its stock fall -1.87% to $145.01. Over the last five days, the stock has lost -1.57%. Neurocrine Biosciences, Inc. shares have risen nearly 10.06% since the year began. Nevertheless, the stocks have risen 36.79% over the past one year. While a 52-week high of $157.98 was reached on 08/01/24, a 52-week low of $103.63 was recorded on 02/07/24. SMA at 50 days reached $141.94, while 200 days put it at $134.15.
Levels Of Support And Resistance For NBIX Stock
The 24-hour chart illustrates a support level at 143.91, which if violated will result in even more drops to 142.82. On the upside, there is a resistance level at 146.81. A further resistance level may holdings at 148.62. The Relative Strength Index (RSI) on the 14-day chart is 48.91, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.51, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 65.31%. Stochastics%K at 42.15% indicates the stock is a holding.
How much short interest is there in Neurocrine Biosciences, Inc.?
A steep rise in short interest was recorded in Neurocrine Biosciences, Inc. stocks on 2024-07-31
The most recent change occurred on August 21, 2023 when Mizuho resumed its ‘”a Neutral”‘ rating for the stock and retained the price target to $113.
